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There is some variation regarding age at initiation of screening for colorectal cancer (CRC) between countries, but the same age of
initiation is generally recommended for women and men within countries, despite important gender differences in the epidemiology
of CRC. We have explored whether, and to what extent, these differences would be relevant regarding age at initiation of CRC
screening. Using population-based cancer registry data from the US and national mortality statistics from different countries, we
looked at cumulative 10-year incidence and mortality of CRC reached among men at ages 50, 55, and 60, and found that women
mainly reached equivalent levels when 4 to 8 years older. The gender differences were remarkably constant across populations and
over time. These patterns suggest that gender differentiation of age at initiation may be worthwhile to utilise CRC-screening
resources more efficiently.
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With more than one million new cases and more than 500000
deaths per year, colorectal cancer (CRC) is the third commonest
cancer and the fourth commonest cancer cause of death worldwide
(Parkin et al, 2005). Owing to its typically slow development, there
is a large potential for reducing the burden of the disease by early
detection and removal of precancerous lesions or early cancer
stages. Various screening examinations, including faecal occult
blood testing (FOBT), sigmoidoscopy, and colonoscopy have
meanwhile been recommended by expert committees and im-
plemented in screening offers in a number of countries (e.g.
Winawer et al, 2003; Schmiegel et al, 2004; Malila et al, 2005; Smith
et al, 2006). Regarding the age at initiation of screening, which is a
crucial parameter for the effectiveness and cost-effectiveness of
screening programmes (Vijan et al, 2001), there is some variation
between countries (typically ranging from 50 to 60 years for the
population at average risk). However, within countries, the same
age of initiation is generally recommended for women and men,
despite important gender differences in the epidemiology of CRC.
In particular, age-specific CRC incidence and mortality are lower
in women than in men, which implies that women reach
comparable levels of CRC incidence and mortality at higher ages
than men. This paper aims to address the question whether and to
what extent these epidemiological differences might be relevant for
defining age at initiation of CRC screening among women and
men.
METHODS
Outcome measure
When attempting to translate the gender differences in the
epidemiology of CRC into gender-specific ages at initiation of
screening, it is first necessary to define an appropriate outcome
measure. In a screening programme that primarily aims at the
early detection of CRC, as applies to FOBT-based screening,
(cumulative) age- and sex-specific CRC incidence appears to be a
natural choice. In a screening programme that aims to detect both
CRC and its precursors (adenomas), as applies to endoscopy-based
screening, the epidemiology of adenomas might also be consid-
ered. However, if the time period until adenomas progress to
cancer is independent of age and sex, additional consideration of
adenoma occurrence would have no impact on the results. If, on
the other hand, progression time differs by age and sex, gender-
specific differences in CRC incidence may actually remain the
more relevant parameter even for these types of CRC screening
programmes. When data on CRC incidence are not available, age-
and sex-specific CRC mortality can be used as a good surrogate
parameter, given that survival differences between female and male
CRC patients are very small (Bossard et al, 2007).
Data sources
Age and sex specific data on CRC incidence and mortality were
obtained for the years 2000–2003 in the US from the National
Cancer Institute’s Surveillance, Epidemiology and End Results
(SEER) Programme (Ries et al, 2006). The incidence data are based
on 17 areas of the US (Atlanta, Connecticut, Detroit, Hawaii, Iowa,
New Mexico, San Francisco-Oakland, Seattle-Puget Sound, Utah,
Los Angeles, San Jose-Monterey, Rural Georgia, Alaska, Greater
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data are based on US national figures.
In addition, the World Health Organisation (WHO) mortality
database, accessed through the website of the International Agency
for Research on Cancer (WHO mortality data base, 2006), was used
to assess the consistency of observed patterns between popula-
tions. National age- and sex-specific mortality data referring to the
year 2001 were obtained for 11 large countries from different parts
of the world: Australia, Asia (Russia, Japan), Europe (France,
Germany, Italy, Poland, Spain, United Kingdom), and North
America (Canada, US). Although data up to the year 2003 were
available for some countries, the latest available data were from
2001 for other countries; we therefore chose this year for our
comparative analyses. Finally, US national mortality data from the
years 1976, 1981, 1986, 1991, 1996, and 2001 were obtained from
the WHO-mortality database to address consistency of observed
patterns over time.
Statistical analysis
Using the SEER incidence data, we first calculated cumulative CRC
incidence within the following 10 years among men and women for
each single year of age between ages 50 and 75. The cumulative
incidence within a given age range approximates the expected risk
of developing a disease within the defined age interval in the
absence of competing causes of death, assuming that age specific
incidence rates remain constant over time (Day, 1987). Starting
from the levels of 10-year cumulative incidence among men at ages
50, 55, and 60 (the most commonly implemented ages for initiation
of CRC screening in existing programmes), we determined at what
ages the same levels of 10-year cumulative incidence were observed
among women. Analogous calculations of ‘risk advancement
periods’ (Brenner et al, 1993) were then carried out for 10-year
cumulative mortality on the basis of the national vital statistics
data. In additional sensitivity analyses, the time interval was varied
between 5 and 15 years.
RESULTS
The SEER incidence database included 74111 men and 72290
women diagnosed with CRC in 2000–2003. Among men,
cumulative incidence in the subsequent 10 years increased from
0.8% at age 50 to 1.2% at age 55 and 1.9% at age 60 (see Figure 1).
Among women, comparable levels of 10-year cumulative incidence
were reached at ages 54, 60, and 66 only, i.e. 4, 5, and 6 years later,
respectively.
Overall, 113174 men and 113454 women died of CRC in the US
in 2000–2003. The 10-year cumulative mortality from CRC in the
subsequent 10 years also steadily increased with age in both sexes,
and it was higher at any age between 50 and 75 years among men
than among women (see Figure 2). Cumulative mortality within
the subsequent 10 years was 0.23, 0.39 and 0.63% at ages 50, 55
and 60, respectively, among men. Again, comparable levels were
reached by women at ages 54, 60, and 66 only, i.e. 4, 5, and 6 years
later, respectively.
Sensitivity analyses using 5- and 15- rather than 10-year
cumulative incidence and mortality in the US as indicators of
CRC risk yielded very similar differences in the age at which
comparable levels were reached among men and women
(differences between 4 and 6 years for 5-year cumulative incidence
and mortality, and between 5 and 7 years for 15-year cumulative
incidence and mortality).
Analogous calculations for 10-year cumulative CRC mortality in
2001 in 11 large countries from different parts of the world showed
very similar age differences between women and men, despite
some major variation in the overall levels of CRC mortality (see
Table 1). The 10-year cumulative mortality seen among men at age
50 was reached by women between ages 54 and 56 in nine out of 11
countries (median: 55 years); slightly lower and higher ages were
only seen for the Russian Federation (52 years), and Japan (57
years), respectively. The 10-year cumulative mortality seen among
men at age 55 was reached by women between ages 60 and 62 in
the same nine countries (median: 61 years). Again, slightly lower
and higher ages were only seen for the Russian Federation (59
years) and Japan (64 years), respectively. The 10-year cumulative
mortality seen among men at age 60 was reached by women
between ages 66 and 68 in nine countries (median: 67 years) and at
ages 69 and 70 in Spain and Japan, respectively.
A time trend analysis on the basis of 10-year cumulative CRC
mortality for the US revealed that the sex differences were
consistently seen throughout the 25-year period from 1976 to
2001. The sex differences even slightly increased over time.
DISCUSSION
Our analyses of age- and sex-specific incidence and mortality of
CRC in the US and 10 other large countries from different parts
of the world indicate that the lower incidence and mortality
among women quite consistently translates to an age difference of
approximately 4–8 years at which comparable levels of risk are
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Figure 1 10-year cumulative incidence of colorectal cancer in
subsequent 10 years among men and women at various ages. The dotted
lines indicate the age differences at comparable levels of cumulative
incidence between women and men. SEER Program, US, 17 registries,
2000–2003 (Ries et al, 2006).
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Figure 2 10-year cumulative mortality from CRC in subsequent 10 years
among men and women at various ages. The dotted lines indicate the age
differences at comparable levels of cumulative mortality between women
and men. US national mortality statistics, 2000–2003 (Ries et al, 2006).
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are closely related to potential benefits of screening, which have to
be weighed against costs and potential adverse side effects in
choosing the age of screening initiation. Our analysis suggests that
the balance in favour of screening is likely to be reached several
years later among women than among men. This finding is
supported by a recent study from Poland among more than 50000
participants of a colonoscopy-based screening programme, where
prevalence of advanced adenomas was higher at each age among
men than among women, prompting the authors to the conclusion
that gender-specific CRC-screening recommendations may be
warranted (Regula et al, 2006). Furthermore, there are indications
both from our analysis and from the literature (Fernandez et al,
2001) that the gender difference in the epidemiology of CRC has
steadily increased during the last few decades. These results may
therefore have important implications for the offer of CRC
screening programmes and their optimisation in terms of cost
effectiveness.
The choice of different, risk adapted ages at initiation of
screening is well accepted and established for CRC risk factors
other than gender, in particular a history of CRC before age 60 in a
first degree relative (Winawer et al, 2003; Schmiegel et al, 2004;
Smith et al, 2006). Although the relative risk of CRC among people
with such a family history compared to those without is larger than
the relative risk of men compared to women (Johns and Houlston,
2001), the prevalence of the former risk factor in the population is
much lower than the ‘prevalence’ of male gender. These patterns
suggest that appropriate differentiation of age at initiation of CRC
screening by gender might be similarly or even more relevant
from a public health point of view than the widely practiced
differentiation by family history.
Another important epidemiological aspect that might be of
importance in the choice of age at initiation of CRC screening is
the differential distribution of CRC location among women and
men. The proportion of cancer in the distal colon and rectum is
considerably lower among women than among men (Stewart et al,
1983; Bonithon-Kopp and Benhamiche, 1999; McCashland et al,
2001). Therefore, the sex difference in distal CRC occurrence is
even larger than the sex difference in overall CRC occurrence.
These patterns suggest that age differences may even be more
relevant for initiation of screening programmes primarily based on
sigmoidoscopy than for screening programmes primarily based on
stool tests or colonoscopy.
Epidemiological data on the occurrence of colorectal neoplasms
are important, but are not the only factors to be considered in the
choice of the age range at which screening is offered. Another
important factor is remaining life expectancy (Ko and Sonnenberg,
2005; Lin et al, 2006), which is of primary relevance for a potential
upper age limit for CRC screening. Given that life expectancy is
generally higher among women than among men, there are further
reasons to define gender-specific age ranges for CRC screening.
Considering potential gender differences in recommended age
ranges for CRC screening, nonepidemiological criteria, such as
complexity of guidelines, also have to be taken into account
(Lieberman, 2005). One might argue that gender-specific recom-
mendations might add another layer of complexity, which could be
a barrier against use of CRC screenings. However, from the
patients’ point of view, schedules for cancer screening are gender-
specific anyway, given that some of the most widely used screening
measures refer to female (breast, cervical) and male (prostate)
cancers. From the point of view of health-care providers, initiation
of CRC screening at different ages for women and men (e.g. 5 years
apart) would not seem to be too much of a challenge either.
In the interpretation of our results, the following limitations
should be kept in mind. Given the lack of national CRC incidence
data for many countries, CRC-mortality data were used along with
CRC incidence data in our comparative analyses. As already
mentioned, CRC mortality should be a good surrogate parameter
given that survival of female and male CRC patients is essentially the
same (Bossard et al, 2007). In fact, exactly the same age differences
by sex were seen for incidence and mortality in our analyses for the
US, where both measures were looked at. Another potential
limitation is that in some of the countries included in this analysis,
some form of CRC screening has already been practiced during the
calendar years included in the analyses. This may have affected CRC
incidence and mortality to some extent. Furthermore, differential
participation in CRC screening among women and men might have
affected the gender differences reported in our analysis. However, in
the years under investigation, the overall impact of CRC screening is
likely to have been limited, and gender differences in screening
utilisation quite small compared to the major gender difference in
CRC incidence and mortality. In particular, participation in
Table 1 Age-adjusted mortality of colorectal cancer among men and women, and ages at which 10-year cumulative mortality among women reaches
levels observed among men at ages 50, 55, and 60
Age-adjusted mortality
a
Age at which 10-year cumulative mortality among women
reaches level observed among men at age
Country Year Men Women 50 55 60
Australia 2001 17.4 11.2 54 61 67
Canada 2001 14.6 9.6 55 61 67
France 2001 15.8 9.0 56 61 68
Germany 2001 18.2 11.7 56 62 66
Italy 2001 15.1 9.3 54 61 68
Japan 2001 16.4 9.5 57 64 70
Poland 2001 18.7 11.5 55 61 68
Russian Federation 2001 18.7 12.8 52 59 67
Spain 2001 17.6 9.6 55 62 69
United Kingdom 2001 15.9 9.5 55 62 67
United States 2001 13.7 9.5 54 60 66
1996 15.0 10.3 53 60 67
1991 16.4 11.2 53 60 66
1986 17.4 12.3 53 59 65
1981 18.0 13.0 52 59 65
1976 18.8 14.5 52 59 65
aDeaths per 100000 person years, adjusted to the world standard population.
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higher among women compared with men in the US (Seeff et al,
2004; Lieberman et al,2 0 0 5 ;M e i s s n e ret al, 2006), and could thus
not explain the lower CRC mortality among women.
Our analysis only considers the ‘net differences’ in CRC
incidence and mortality between women and men, which might
be owing to a variety of reasons. There are suggestions that
hormonal effects, both up to menopause and through hormonal
replacement therapy (HRT) may protect from or delay develop-
ment of CRC (Beral et al, 2002). To the extent that the recent
reduction in HRT use following publication of the results of the
Women’s Health Initiative Randomised Trial (Rossouw et al, 2002;
Hersh et al, 2004) and the Million Women Study (Beral, 2003;
Faber et al, 2005) might increase CRC incidence among women,
the previous trend of an increasing gender gap in CRC incidence
and mortality might be slowed down or possibly reversed.
Our analyses do not allow a general recommendation regarding
the best age for initiation of CRC screening. The latter is likely to
vary between populations, owing to between-population variation
in CRC incidence and mortality, and in CRC screening and
treatment costs. Our results suggest, however, that the optimal age
for screening initiation is likely to be around 5 years higher for
women than for men within populations, assuming that screening
is equally effective in women and men. This could imply either
postponement of age at initiation of screening among women or
advancement of age at initiation among men compared to
nongender-specific-screening schemes. It should also be kept in
mind that our results pertain to people at average risk of CRC, and
they should therefore not be generalised to specific screening
strategies for high-risk groups.
In summary, our results suggest that gender specific differentia-
tion of age at initiation of CRC screening by about 5 years might
help to utilise screening resources in a more efficient manner.
Gender specific screening schedules should therefore deserve
careful attention in the design and evaluation of CRC screening
programmes.
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